



Structure of the LeuT-desipramine complex suggests
how antidepressants inhibit neurotransmitter reuptake
(R21-GM075936)



Da-Neng Wang
Skirball Institute
New York University School of Medicine

Depression




Most common psychiatric disorder

17 % prevalence rate



120 million patients world wide

Antidepressants as major medication







Response rate ~70%

Annual sales US\$ 16.7 billion




Neurotransmitter reuptake and its inhibition

Neurotransmitters






VMAT - GlpT(2003)

Receptor



Neurotransmitter reuptake and its inhibition


Neurotransmitters



Transporter - inhibitor

- SERT - TCA, SSRI, SNRI
- NET - TCA, NRI, SNRI
- DAT - Ritalin, cocaine

Receptor



Competitive inhibition of human neurotransmitter transporters





FIG. 1. Inhibition of 5-hydroxytryptamine (5-HT) transport by imipramine. Initial rates of 5-hydroxytryptamine transport were measured using a 10-s incubation at 37°C as described previously (5) in the presence and absence of 30 nM imipramine. The data are presented according to the method of Hofstee (17). ○—○, control; ■—■, imipramine. The lines were calculated from a linear least squares fit of the data.

Displacement model



Talvenheimo, (1979)


Key questions

Where is the drug-binding site in the protein?

Are the drug-binding site and the substrate-binding site overlapping?

What is the nature of the competitive inhibition?

Neurotransmitter:sodium symporters (NSS)




And bacterial NSS proteins

Drug binding to SERT, NET and DAT (IC₅₀, nM)


Drug	hSERT	hNET	hDAT	<i>Drosophila</i> DAT	<i>C. elegans</i> DAT
Desipramine	64	4.2	82,000	18	3
Imipramine	8.0	70	25,600	30	1
Fluoxetine	7.3	1,020	19,500	240	170
Sertraline	58	1,200	1,100		
Citalopram	5.4	>1,000	10,000		
Paroxetine	0.25	312			
Nisoxetine	400	5.3	497		
Reboxetine	129	1.1			
Venlafaxine	39	210	9,300		
Methylphenidate	>50,000	514	84		
Cocaine	410	910	278	2,660	5,000

Leucine transporter LeuT from *Aquifex aeolicus*

25% sequence identity, ~45% similarity to human NSS proteins




1.65 Å structure of LeuT in drug-free form




Structure solved by the Gouaux lab
in 2005

LeuT + 1 Leucine + 2 Na⁺




Yamashita, 2005



Measurements of antidepressant binding to LeuT


Scintillation proximity assay





Purified LeuT bound with radioactive substrate

Scintillation beads


Quick & Javitch, (2007)






Desipramine binding to LeuT is not competitive





Desipramine-binding site and the leucine-binding site are separated by the extracellular gate







Binding pocket for desipramine in LeuT



Desipramine binding slows down substrate release



Homology modeling of SERT, NET and DAT



Probing desipramine-binding site in human proteins

Affinity of human NSS transporters
to desipramine (IC₅₀)

Human NET 4.2 nM

Human SERT 64 nM

Human DAT 82,000 nM

NET

SERT

DAT



Probing desipramine-binding site in human proteins

Affinity of human NSS transporters
to desipramine (IC₅₀)


Human NET	4.2 nM
Human SERT	64 nM
Human DAT	82,000 nM

↑
NET
NERT
DET



Gain of function mutagenesis in DAT




DAT-F472L: 79% decrease in IC₅₀




Gain-of-function mutagenesis in SERT



SERT-K490T: 51% decrease in IC₅₀



Summary



In LeuT, desipramine binding site at the extracellular gate, separated from the leucine binding site

Desipramine inhibits transport by preventing Substrate release to the cytosol

The drug binding site and inhibition mechanism are probably conserved in human SERT, NET and DAT

The structural information can help with drug design

Acknowledgements

Wang Lab

Regina Goetz
Nathan Karpowich
Christopher Law
Zheng Zhou



Reith Lab (NYU Psychiatry)

Maarten Reith
Juan Zhen

Synchrotron Source
X29 & X25 at NSLS/Brookhaven

Financial Support
NIH-Roadmap, NIH-PSI-II

